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RESUMEN
Objetivo. El objetivo principal de este artículo de revisión es proporcionar información sobre las ventajas 
de las proteínas y péptidos a través de diferentes vías de administración de fármacos, dirigidos a un sitio 
en particular y su implicación en el sistema de administración de fármacos.
Métodos. Con ese objetivo, los sitios web de PubMed, HCAplus, Thomson, se utilizaron como las prin-
cipales fuentes para realizar la búsqueda de los artículos de investigación más importantes publicados 
sobre el tema. La información fue luego cuidadosamente analizada, destacando los resultados más im-
portantes en el desarrollo de proteína y péptido de direccionamiento de drogas, así como su actividad 
terapéutica.
Resultados. En los últimos años muchos investigadores utilizan las proteínas y los péptidos como un 
sitio diana de fármaco por un sistema de administración diferente. Las proteínas y los péptidos se utili-
zan como agentes terapéuticos específicos y eficaces, debido a la inestabilidad y los efectos secundarios 
de su uso es complicado. Las proteínas quinasas son reguladores importantes de la mayoría, si no todos, 
los procesos biológicos. La actividad anormal de proteínas y péptidos se ha implicado en muchas en-
fermedades humanas, tales como diabetes, cáncer y trastornos neurodegenerativos.
Conclusión. Finalmente concluyó que la proteína y el péptido se utilizaron en fármaco que se dirige 
al sitio específico y también se utiliza en diferentes estados de enfermedad como el cáncer, la diabetes, 
como sustancias inmunomoduladora, efectos neurodegenerativos y actividad antimicrobiana.
Palabras clave: proteína, péptido, liberación controlada, polímero bioerosionable.
ABSTRACT
Aim. The main aim of this review article is to provide information like advantages of protein and pep-
tides via different routes of drug administration, targeted to a particular site and its implication in drug 
delivery system. 
Methods. To that aim, from the web sites of PubMed, HCAplus, Thomson, and Registry were used as the 
main sources to perform the search for the most significant research articles published on the subject. The 
information was then carefully analyzed, highlighting the most important results in the development of 
protein and peptide drug targeting as well as its therapeutic activity.
Results. In recent years many researchers use protein and peptide as a target site of drug by a different 
delivery system. Proteins and peptides are used as specific and effective therapeutic agents, due to in-
stability and side effects their use is complicated. Protein kinases are important regulators of most, if not 
all, biological processes. Abnormal activity of proteins and peptides has been implicated in many human 
diseases, such as diabetes, cancer and neurodegenerative disorders. 
Conclusions. It is concluded that the protein and peptide were used in drug targeting to specific site 
and also used in different diseased states like cancer, diabetes, immunomodulating, neurodegenerative 
effects and antimicrobial activity.
Keywords: Protein, Peptide, Controlled release, Bioerodible polymer.
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INTRODUCTION
Protein and peptide enhance the successfully delivery of the 
drug to the desired site of action. In past twenty years many 
biopharmaceutical process development aspects have been 
studied by researchers. For the production of many phar-
maceutical proteins that have been well characterized and 
overcome the problem associated with cell culture, purifi-
cation, recovery and fermentation 1. Thus, the successful 
development of protein and peptide formulations is totally 
depending on the study of in vitro, in vivo drug characteri-
zation and its intended application 1. The recently protein 
and peptide show great progress to understand the erosion 
mechanism of biodegradable polymer and the preparation 
of controlled release devices. The results provide useful in-
formation on the microstructure and chemical environment 
inside these polymers during erosion. Many protein and 
peptide cannot be administered orally because it degraded 
inside the gastrointestinal tract (GI tract) 2 due to their short 
half life in the body fluids. 
These limitations forced the preparation of controlled re-
lease dosage form and enhance the protein and peptide 
stability and drug activity for long period of time after its 
application. Processing of this substance into dosage forms 
at all times not easily achieved. Many of them have limited 
chemical and physical stability. Common instabilities are 
irreversible aggregation (J) 3, oxidation 4 or conformational 
changes 5 all of which may affect activity. The controlled re-
lease devices for buccal, oral, nasal, rectal, parenteral, vagi-
nal and transdermal routes have been prepared 6,7. In the 
last few decades number of bioactive protein and peptide 
have discovered due to the progress in the field of biology 
and biochemistry. Insulin is a classical example, which is 
mostly used in medical therapy. The rapid development of 
biotechnology and progress in peptide and protein chemis-
try allowed the mass production of many compounds and 
made their broad introduction into medical therapy pos-
sible 8. 
In biological processes protein and peptides play important 
role such as regulator in most cases not all. Their abnormal 
activity has been implicated as causal factors in many hu-
man diseases, including cancer, diabetes and neurodegen-
erative disorders 9-11. Pharmaceutical carriers were used to 
increase the stability, improve their efficacy and decrease 
undesired side effects and to assist intracellular delivery of 
the drugs in most of the cases 8,12.
STRUCTURE OF PROTEIN AND PEPTIDES
The Protein are complex of large molecules, consist of one 
or more amino acids in specific order. The protein and pep-
tide acquire three dimensional conformations and protein 
structure is directly related to its function. It means that if 
the structure or shape of protein disrupted the function will 
also disrupted. There are four types of protein structures13 
(Figure 1), namely, (a) primary structure (b) secondary 
structure (c) tertiary structure (d) quaternary structure.
A target peptide (Table 1) is short peptide chain of amino 
acids (usually 3-70) that directs the transport of protein 
and peptide to specific region in the cell, such as includ-
ing mitochondria, nucleus, endoplasmic reticulum (ER), 
apolpast, chloroplast, peroxisome and plasma membrane. 
Signal peptidase enzyme cleaved the target peptide from 
protein after those proteins were transported14. The amino 
acids joined together by amide linkage15 known as peptide 
bond (Figure 2).
Figure 1. Four type of protein structure. Figure 2. Structure of peptide bond
167Ars Pharm. 2015; 56(3): 165-177
Protein and Peptide in Drug Targeting and its Therapeutic Approach
Table 1. Examples of target peptides 
S. N. Cell Peptide Chain
1. Transported to the nucleus (NLS) -Pro-Pro-Lys-Lys-Lys-Arg-Lys-Val-
2.
Transported to the secretory pathway (plasma membrane of 
prokaryotes and endoplasmic reticulum of eukaryotes)
H2N-Met-Met-Ser-Phe-Val-Ser-Leu-Leu-Leu-Val-
Gly-Ile-Leu-Phe-Trp-Ala-Thr-Glu-Ala-Glu-Gln-
Leu-Thr-Lys-Cys-Glu-Val-Phe-Gln-
3. Retention to the endoplasmic reticulum -Lys-Asp-Glu-Leu-COOH
4. Transported to the mitochondrial matrix
H2N-Met-Leu-Ser-Leu-Arg-Gln-Ser-Ile-Arg-Phe-
Phe-Lys-Pro-Ala-Thr-Arg-Thr-Leu-Cys-Ser-Ser-
Arg-Tyr-Leu-Leu-
5. Transported to the peroxisome (PTS1) -Ser-Lys-Leu-COOH
6. Transported to the peroxisome (PTS2) H2N-----Arg-Leu-X5-His-Leu-
ADVANTAGES OF PROTEIN AND PEPTIDES IN DIF-
FERENT ROUTES
Protein and peptides delivery of drugs provides several ad-
vantages when drug delivered by various routes, some of 
the mentioned below:
Buccal route 
When the drug delivered via buccal routes it provides 
much less pain, irritation in case of long term of treatment. 
It can be easily attached and removed without any discom-
fort and easily accessible and acceptable by patients 16. 
Nasal route 
Nasal route is simple, convenient and provide rapid onset 
of drug action and also avoid the first pass metabolism 13,17.
Rectal route 
A large dose of drug can be administered by rectal route, 
drugs can be target to lymphic system, it avoids presys-
temic or first pass metabolism and suitable for drugs that 
cause nausea/vomiting and irritation in GI tract on oral 
administration 16. 
Pulmonary route 
Pulmonary route of drug administration provides direct 
route to the circulation, safe route for drug entry even in 
patient with lung disease. Less dose required, less pain or 
discomfort and improve patient compliance 13,18,19.
Transdermal route
Transdermal route provides controlled and sustained re-
lease of drugs. Self administered and improve patient com-
pliance due to its convenience and ease of use. Reduced 
side effects and avoid the hepatic first pass effect and gas-
trointestinal breakdown of drugs. Quick abrupt termina-
tions of drug effect by easily remove the delivery system 
from the skin surface 20-23.
PEPTIDE AND PROTEIN DRUGS – BRIEF OVER-
VIEW AND DELIVERY PROBLEMS
Many proteins and peptides acquire biological activity that 
makes them potent therapeutics. The enzymes represent 
an important and, probably, the best investigated group of 
protein drugs 24-26. The insulin peptide hormones used most 
likely than that of other hormone. To the treatment of pitui-
tary and gastrointestinal (GI) tumors, somatostatin analogs 
peptides such as lanreotide, octreotide and vapreotide be-
come available in the clinics 27. Antibodies against certain 
cancer-specific ligands can also be considered as protein 
anti cancer drugs 28,29. Still, the use of proteins and peptides 
as therapeutic agents is hampered by the whole set of their 
intrinsic properties associated with their nature as complex 
macromolecules, which are, as a rule, foreign to the recipi-
ent organism.
Stability of protein may vary at different condition of phys-
iological pH and temperature, most of the peptide espe-
cially protein show low stability at normal physiological 
pH and temperature. Due to receptor interaction most of 
the protein and peptide and antibodies exert their action 
extracellularly. Many others, however, have their targets 
inside the cell. In the latter case, low permeability of cell 
membranes to macromolecules often represents an addi-
tional obstacle for the development of peptide-based and 
protein-based drug formulations 30.
PEPTIDES AS COMPETITIVE INHIBITORS
The amino acid sequences responsible for the protein ki-
nases specificity to substrate phosphorylation which leads 
to phosphorylation called as consensus sequences. The 
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numbers and types of interactions with residues surround-
ing the phosphorylation site vary considerably among ki-
nases, reflecting differences in sequence specificity. By vir-
tue of that consensus sequence can serve as a template for a 
peptide that will acts as a competitive inhibitor 31,32.
PEPTIDES COMPETING WITH ANCHORING AND 
TARGETING PROTEINS
Modular binding partners target some Ser/Thr kinases to 
their specific substrates via changes in cellular localization. 
Binding of a peptide to this targeting domain may prevent 
the interaction of the kinase with its substrates. The Protein 
kinase C isoforms are known to translocate from cytosol to 
particulate fractions in response to various stimuli. A fam-
ily of adaptor molecules, termed RACKs (Figure 3) (from 
Receptors for Activated C-Kinase), interact with the vari-
ous Protein kinase C isozymes and facilitate their cellular 
translocation 33,34. The RACK binding domain is a short 
sequence located in the Protein kinase C’s N terminal-sub 
domain and is different in each isoform. Thus, the trans-
location of Protein kinase C isoforms could be disrupted 
selectively using peptides derived from the specific RACK 
docking region 35,36. The use of such peptides has enabled 
analysis of the functions of individual Protein kinase C 
isozymes. For example, peptides derived from the C-2 re-
gion of PKC-β II prevented hormone-induced membrane 
translocation of PKC β II and inhibited insulin-induced 
Xenopusoocyte maturation 37.
Figure 3. Structure of Receptors for Activated C-Kinase 
(RACK)
FORMULATION DEVELOPMENT CONSIDERA-
TIONS
Novel delivery system includes the complete characteri-
zation of the drug properties and drug stability in differ-
ent formulations, is the main key for development of any 
protein and peptide formulation. Typically, a formulation 
scientist will begin by considering the physicochemical 
properties of the protein such as the isoelectric point, mo-
lecular weight, glycosylation or other post-translational 
modification, and overall amino acid composition. These 
properties along with any known behavior of the drug in 
different solutions (e.g. different buffers, cofactors, etc.) 
as well as its in vivo behavior should guide the choice of 
formulation components for testing in the initial screen of 
candidate formulations. The potential candidate formula-
tions are composed of U. S. Food and Drug Administration 
(FDA) approved buffer components, excipients, and any 
required cofactors (e.g. metal ions). Often, the first choice of 
candidate formulations is based upon the previous experi-
ence of the formulation scientist with other proteins or pep-
tides and, in many cases; a simple phosphate buffered sa-
line solution may be one of the initial candidates. The pH of 
the solution impacts major degradation pathway. Thus, the 
initial formulations also assess the pH dependence of the 
degradation reactions and the mechanism for degradation 
can often be determined from the pH dependence 38. The 
stability of each solution quickly analyzed by the formula-
tion scientist. Rapid screening methods usually involve the 
use of accelerated stability at elevated temperatures (e.g. 
40°C) 39-42.
Many proteins and peptides shows extensive degradation 
without affecting their safety and efficacy, such as recom-
binant human growth hormone (rhGH) is fully bioactive 
and nonimmunogenic but 70 % deamidated, this value of 
degradation not acceptable by regulatory agency standard 
for therapeutic protein 43.
Scientists must consider potential conditions and all the 
major degradation route of optimization to fulfill the regu-
latory requirements for a stable formulation. Surfactant is 
added in case of aggregation or sugar can prevent denatur-
ation process, which leads to irreversible aggregation. The 
use of amine buffers (like Tris, ammonium, or imidazole) 
may slow the deamidation rate when degradation rate 
dominant 44. In another degradation pathway, for example, 
by adding surfactants or other polymers to prevent aggre-
gation, the residual peroxide in the surfactant may cause a 
more rapid oxidation 45.
To decrease the deamidation rate pH of the formulation 
must be reduced in some cases. Reduction of pH may also 
alter the protein solubility, since many proteins have iso-
electric points at or near the optimal pH (pH 5-6) for mini-
mizing the deamidation rate. For each protein formulation, 
all the degradation pathways must be evaluated and often 
a balance must be achieved between the different degra-
dation pathways. The researchers have options to develop 
solid formulation like lyophilized powder. The removal of 
excess water from the formulations decreases rate of the 
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degradation in process of deamidation and hydrolysis. The 
residual moisture in a solid protein or peptide formulation 
can contribute to the physical stability of the protein by pre-
venting its denaturation and subsequent aggregation upon 
reconstitution. Recent studies on lyophilization of proteins 
without excipients required some residual water for stabil-
ity purpose 46. Different routes of protein and peptide deliv-
ery and polylactide applications presented in Table 2 and 
Table 3 respectively.
Table 2. Routes of delivery for proteins and peptides 45,46
S.N. Delivery Routes
Formulation and Device 
Requirements
Commercial Prod-
ucts
Manufacturer
1. Invasive
Direct Injection
Liquids or reconstituted solids, 
syringes
intravenous (i.v.) Activase® Genentech, Inc.
subcutaneous (s.q.) Nutropin® Genentech, Inc.
intramuscular (i.m.) RecombiVax® Merck & co.
intracerebral vein (i.c.v.)
Depot system
Biodegradable polymers, li-
posomespermeable polymers 
(not degradable),microspheres, 
implants
LHRH analogs (s.q. or 
i.m.)
Lupron Depot®
Zoladex®
Decapeptyl®
Takeda Pharmaceu-
ticals.
Imperial Chemical 
Industries, Ltd.
Debiopharm
2. Noninvasive 
Pulmonary
Liquids or powders formulations,
nebulizers, metered dose inhalers,
dry powder inhaler
Pulmozyme® Genentech, Inc.
Oral
Solids, emulsions, microparticulate,
absorption enhancer
Nasal
Liquids, usually requires permea-
tion
enhancer
Synarel® Syntex Corporation
Topical
Emulsions, creams or pastes 
(liposomes)
Transdermal
Electrophoretic (iontophoresis),
electroporation, chemical permea-
tion
enhancer, prodrug, ultrasonic
Buccal, Rectal, Vaginal
Gel, suppositories, bioadhesives, 
particles
170 Ars Pharm. 2015; 56(3): 165-177
Keservani, R.; Sharma, A. & Jarouliya, U.
Table 3. List of polylactide for controlled release of proteins or peptides and its application 47-60
S.N. Protein or Peptide Polymer (*) Application
1.
Bone morphogenetic
protein
PLA-PEG copolymer (650 Da PLA - 200 
Da PEG)
Bone formation
2.
Transforming
growth factor-βι
50:50 PLGA (40-100 kDa) (+ demineral-
ized bone matrix)
Bone formation
3. Thyrotropin 75:25 PLGA (11 kDa)
Central nervous
system dysfunction
4.
Growth hormone
releasing factor
75:25 PLGA (91 kDa)
Growth hormone
Deficiency
5. Somatostatin analogue 55:45 PLGA (23-76 kDa) Acromegaly, tumors
6. Neurotensin Analogue PLA (2-6 kDa) Psychotropic
7. Cyclosporin A
50:50 PLGA
(0.44 & 0.80 dL/g)
Immunosuppression
8.
Colonizing factor
antigen (E. coli)
PLGA (0.73 dL/g) Oral vaccine
9.
Cholera toxin Β
subunit
PLA (2 kDa ) Oral vaccine
10.
Diphtheria toxoid
formilin treated
PLA (49 kDa) Vaccine
11. Ovalbumin
50:50 PLGA (22 kDa)
85:15 PLGA (53 kDa)
Vaccine
12. Tetanus toxoid 50:50 PLGA (100 kDa) Vaccine
13. LHRH antagonists
50:50 PLGA
75:25 PLGA
Tumor suppression
14.
Horse radish
peroxidase
Bovine serum albumin
75:25 PLGA (10 kDa)
Marker proteins
Mechanistic studies
(*) X: Y PLGA indicates the mole fraction (%) of lactide (X) and glycolide (Y) in the copolymer. The polymer size is reported as either 
molecular weight in kilo Daltons (kDa) or intrinsic viscosity in decaliters/gram. Some references did not provide complete descrip-
tions of the polymer.
THE BASIC CONCEPT FOR DRUG DELIVERY FROM 
BIOERODIBLE POLYMERS
Polymer matrix was represented by two dimensional com-
putational grids, and each of grid point represents either 
an amorphous or crystalline part of the polymer matrix. 
The erosion of polymer mainly depends on two features 
(a) contact with the degradation medium (b) crystalline or 
amorphous nature of matrix. Polymer that’s not contact 
with water will not erode. Pixels on the surface of the poly-
mer matrix or next to an eroded neighbor have contact to 
water. The amorphous parts of polymer erode faster than 
the crystalline matrix 62.
CONTROLLED RELEASE DEVICES FOR THE DELIV-
ERY OF PROTEINS AND PEPTIDES FROM POLY-
MERS
Biodegradable and non degradable polymers have been 
used in controlled release delivery of proteins and pep-
tides. Direct diffusion through a non degradable polymer 
matrix is not possible due to the high molecular weight 
of proteins 63. By the introduction of a network of pores 
in manufacturing, however, the release of such large com-
pounds does occur 64. Another possibility is the creation of 
hydrophilic pathways using swellable polymers, or em-
bedding the compounds into gels. In the case of biodegrad-
able polymers, pores are created upon erosion of the poly-
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mer matrix enabling the release of proteins from the dosage 
form. All of these options have certain advantages and 
disadvantages. Embedding suspended compounds into a 
non-degradable matrix prevents some of the protein from 
being released 65, or might cause some instability due to the 
intense contact with organic solvents 66. Their disadvantage 
with respect to parenteral application, however, is the need 
for removing such systems after therapy. By using gels as 
a carrier, the protein may be released very quickly if not 
combined with some other sort of material67,68. Degradable 
polymers change their properties substantially during ero-
sion, a characteristic which may or may not be beneficial for 
the stability of proteins and peptides. In general, decisions 
about the suitability of a release device for specific proteins 
or peptides and appropriate manufacturing technology 
must be made on a case by case basis. In the following sec-
tion, they provide a number of examples from the progress 
they made in the delivery of proteins from polymers.
BIODEGRADABLE POLYMERS FOR IMMUNIZA-
TION
In seventies, the idea of polymers were using as antigens 
releasing carriers for the simulation of response 69. Due 
to their progress and ease of application, potential effi-
cient carriers (microspheres) emerged to enhance immune 
response 64. They have so far been used for a number of 
vaccines 70-72. These microspheres were made from poly-
mers based on poly-lactic acid (PLA) and its copolymers 
with glycolic acid (PLGA). For these applications, loading 
a polymer with a high molecular weight protein requires 
adjusting the desired release rate and preventing the pro-
tein’s loss of activity. In an attempt to develop a controlled 
release system for vaccination against tetanus, Sluzky et al. 
investigated the design of microspheres with a desired re-
lease rate and methods to maintain the imunogenicity of 
the processed tetanus toxoid 73.
APPLICATION OF PROTEIN AND PEPTIDES IN DIS-
EASES
Protein and peptides widely used in the management 
and treatment of various diseases such as cancer manage-
ments74, cancer therapy75, diabetes therapy76, Antimicrobial 
activity77,78, Peptides and peptidomimetics can function as 
immunomodulating agents by blocking the immune re-
sponse79,80, neurodegenerative diseases 81 etc. 
Cancer therapy and managements
Gene et al., describes a number of peptide based therapies 
we have developed to target theses pathways, and which 
are currently being tested in preclinical models. Therapeu-
tics are based on a synthetic polymeric carrier elastin-like 
polypeptide (ELP), which can be synthesized in various se-
quences and sizes to stabilize the therapeutic peptide and 
avoid crossing the placental interface. This prevents fetal 
exposure and potential developmental effects 82. 
Targeted delivery by cell-targeting peptides (CTPs) with 
the ability to recognize cancer cells is particularly attractive 
for cancer therapy; the use of these peptides has increased 
the specificity and efficacy of drug delivery while reducing 
side effects in a model 83. PEGA, a homing peptide used in 
the diagnosis of breast cancer, this peptide conjugated to 
the cell-penetrating peptide pVEC was taken up by differ-
ent breast cancer cells 84. Peptide D2A21 as therapeutic for 
several types of cancer and has been developing this pep-
tide gel formulation as a wound healing product to treat in-
fected burns and wounds. A TAT peptide derived from the 
N-terminus of p53 has been used in the application of sev-
eral tumor suppressor and apoptotic genes, TAT was fused 
to a peptide derived from the VHL tumor suppressor gene 
that inhibits insulin-like growth factor-I receptor (IGF-IR) 
signaling in renal cell carcinomas 85. Another study done 
by Su et al., observed that naturally existing anti-cancer 
bioactive peptide obtained from liver (ACBP-L) alone or in 
combination with the low dose Cisplatin improves quality 
of life in the xenograft tumor model having human gastric 
cancer 86. The bioactive peptide RRM-MV obtained by the 
resonant recognition model and Myxoma virus (RRM-MV), 
mimicks the bioactivity of specific MV proteins and evalu-
ated the suitability of RRM-MV for human skin cancer 
therapy 87.
Diabetes therapy 
In the study by Kaspar et al. (2013), recent successes in the 
development of peptides as therapeutics, most notably 
glucagon-like peptide 1 receptor (GLP-1R) agonists such as 
Lixisenatide (Lyxumia1), a GLP-1R agonist, was approved 
as a treatment for type 2 diabetes88. It competes with two 
other GLP-1R agonist peptides, exena-tide and liraglutide, 
for type 2 diabetes, they are administered subcutaneous-
ly. The GLP-1R agonist administered s.c. weekly is being 
compared to other diabetes drugs (i.e. exenatide, insulin 
glargine, metformin, sitagliptin, liraglutide) or placebo in 
type 2 diabetes patients. It acts (e.g. cell-targeting peptides, 
cell-penetrating peptides) by linking the peptides to vari-
ous molecular formats (e.g. peptides linked to small mol-
ecules, lipids, carbohydrates, biopolymers, polyethylene 
glycol or proteins) and GLP-1R is able to normalize the 
levels of blood glucose in Type 2 diabetes through several 
mechanisms: the release of insulin is stimulated and the 
release of glucagon is suppressed89. In the another study 
by Wahren et al., C-peptide activates insulin receptor tyros-
ine kinase phosphorylation, and glycogen synthase kinase 
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3 phosphorylation , with downstream effects leading to 
GLUT mobilization, promotion of amino acid uptake, and 
glycogen synthesis, suggesting that C-peptide signaling 
may cross-talk with the insulin pathway at the level of the 
insulin receptor 90. Several clinical studies, with C-peptide 
replacement in patients with type 1 diabetes, show benefi-
cial effects on somatic and autonomic Diabetic peripheral 
neuropathy (DPN), also the C-peptide mediates reduction 
of glomerular hyperfiltration and decrease of urinary al-
bumin excretion in the diabetic state 91. Another protein 
peptide in diabetic study is G-protein-coupled receptors 
(peptide-binding GPCRs) that play an important role in the 
pathophysiology of vascular dysfunction during diabetes92.
Immunomodulating agents
The immunomodulatory action of biopeptides is related 
to the stimulation of proliferation of human lymphocytes 
and macrophages phagocytic activity 93. Lactoferrin (milk 
protein peptide) and its derivatives affect the production of 
cytokines involved in immune reactions of the organism94. 
LF-derived peptides have clinical applications due to their 
chemopreventive and immunomodulatory properties 95. 
α-lactalbumin (whey protein fraction of bovine milk) has 
immunomodulatory properties, whereas products of its 
degradation by trypsin and chemotrypsin (f1 – 5, f17 – 31-
SS-f109 –114 and f61 – 68-SS-f75 – 80) or pepsin exhibit both 
immnunomodulatory and antimicrobial properties against 
bacteria, viruses and fungi 96. Acidic peptides derived from 
β-Lactoglobulin under the action of peptidases of Lactobacil-
lus paracasei decreased the stimulation of lymphocytes and 
regulated production of IL-10, IFN-γ and IL-4 this indicates 
eliminating allergic reaction in cow milk 97. Casein fraction 
and its derived peptide (isracidin) of milk total protein, is 
a rich source of bioactive peptides that stimulate and aid 
the immune system 98. In the study by Rodrigo and Albani, 
Peptides derived from the E. coli heat shock protein (hsp) 
dnaJ are antigenic in human autoimmune disorder rheu-
matic arthritis 99. T cell recognition of these peptides is as-
sociated with TH-I type and pro-inflammatory responses, 
including production of TNF-α and IFN-g in the pathogen-
esis of autoimmune inflammation. Another studied pep-
tide LL-37 is a human antimicrobial peptide derived from 
cathelicidin has anti-endotoxic activity, induces chemokine 
production, promotes IL-1b secretion, but inhibits inflam-
matory responses to certain TLR ligands 100,101. Neutrophils 
LL-37 and defensins are produced by neutrophils, stored 
within neutrophil granules and play an important microbi-
cidal role in phagolysosomes.
Neurodegenerative diseases
There are currently no effective drugs for the treatment of 
neurodegenerative diseases; potential therapeutic targets 
for symptomatic treatments of neurodegenerative dis-
eases may include neuroprotective factors, neurotrophins 
and neuroprotective peptides 102,103. Peptides like NAP 
(NAPVSIPQ) derived from activity of neuroprotective 
protein(NAP) and ADNF-9 peptide derived from activity-
dependent neurotrophic factor (ADNF) in the treatment of 
Alzheimer’s disease (AD) and Amyotrophic lateral scle-
rosis (ALS) disease. ADNF-9 has been found to protect 
against Aβ, apolipoprotein E deficiencies, and oxidative 
stress, as well as increasing synapse formation. Colivelin 
another protein peptide also has potential neuroprotecrive 
effect in neurodegenerative diseases such as AD 104. NAP 
mimics the neuroprotective activity of ADNP in its abil-
ity to cross then blood-brain barrier, interact with tubulin, 
enhance assembly of microtubules, and promote neuronal 
outgrowth in AD and ALS disease 104. In the another discov-
ery of poly Q binding protein (QBP1) peptide, these QBP1 
specifically binds to the expanded polyQ stretch and inhib-
its its misfolding and aggregation, resulting in suppression 
of neurodegeneration in cell culture and animal models of 
the polyQ diseases (Huntington’s disease, spinocerebellar 
ataxia different types, dentatorubral pallidoluysian atro-
phy, and spinobulbar muscular atrophy (SBMA)] 106.
Antimicrobial activity
Antimicrobial peptides (AMPs) are widely distributed 
in nature, are found in species ranging from bacteria and 
insects to mammals 107. Most of these peptides are synthe-
sized as a prepropeptide consisting of an N-terminal signal 
sequence, a pro segment and a C-terminal cationic peptide 
that demonstrates antimicrobial activity after it is cleaved 
from the rest of the protein 108. Compared to conventional 
anti-infective agents, some AMP may kill bacteria but also 
simultaneously neutralize released pathogenic factors, like 
lipopolysaccharide (LPS) or lipoprotein (LP). AMPs have 
anti-Gram-positive and -negative effects 109 as well as anti-
viral and anti-yeast effects. Peptides have shown potential 
and desirable therapeutic properties like antimicrobial, an-
tiviral, anticancer and contraceptive activities. Members of 
the major groups of antimicrobial peptides have been clas-
sified mainly on the basis of their biochemical (net charge) 
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and/or structural features (linear/circular/amino acid 
composition). 
Cationic peptides
This is the largest group and the first to be reported, being 
widely distributed in animals and plants. On the basis of 
their structural features, cationic peptides can be divided 
as well into three different classes: (1) linear peptides form-
ing-helical structures (such as Cecropins) ; (2) cysteine-rich 
open ended peptides containing single or several disulfide 
bridges (such as Defensins); and (3) molecules rich in spe-
cific amino acids such as proline, glycine, histidine and 
tryptophan (such as amino-acid enriched class) 110. Some 
other cationic peptides include, Thionins (plant peptides) 
111 and histone derived compounds, beta-hairpin, cathelici-
dins and thrombocidins.
Anionic peptides
This is a smaller group of antimicrobial peptides which in-
cludes; Neuropeptide derived molecules,Oxygen-binding 
proteins, Aromatic dipeptides and Aspartic-acid-rich mol-
ecules. Some other AMPs Bacterial ribosomes synthesize 
antimicrobial peptides which are generally called as bac-
teriocins (in bacteria), cecropins, Drosomycin and metch-
nikowin (in insect). These peptides however, have certain 
properties in common. They all have an affinity for mem-
brane lipids and their specificity for microbial membranes 
in many cases has been shown to be related to the positive 
charge on the peptide favouring interaction with the ex-
posed anionic lipids of microorganisms. The peptides may 
form pores in the membrane allowing for leakage of ions 
and other materials from the cell. The activity of the pep-
tide is explained by mechanisms like carpet, barrel stave, 
toroidal along with these mechanisms, it shows an intracel-
lular killing activity which affects the nucleic acid of the 
microorganism 112.
Numerous studies focus on multipotential activity of lacto-
ferricin (Lfcin) that is a product of hydrolytic degradation 
of lactoferrin (LF). Lactoferrin itself exhibits a strong bacte-
ricidal activity through its ability to bind iron. This peptide 
shows a considerably higher antimicrobial activity than 
the native protein 113. Lactoferrampin (Lfampin) is another 
peptide derived from lactoferrin. It has a wide spectrum 
of antifungal and antibacterial properties. The peptide ex-
erted antifungal (against Candida) activity higher than LF 
and was also active against Bacillus subtilis, Escherichia coli 
and Pseudomonas aeruginosa 114. Lactoferrin and its deriva-
tives show the antibacterial activity in vitro against various 
pathogens, e.g. Clostridium perfringens, Candida albicans, 
Haemophilus influenzae, Helicobacter pylori, Pseudomonas aer-
uginosa, Staphylococcus aureus, Streptoccccus mutans, Vibrio 
cholerae as well as antiviral activity against hepatitis C and 
B virus; HIV-1; poliovirus; rotavirus; and herpes simplex 
virus 115. Hydrolysis of αs2-casein (by chymosin acting) re-
sults in releasing casocidin, this peptide shows antibacterial 
properties. It was also reported that antibacterial peptides 
obtained from αs2-casein (i.e. f183-207 and f164-179) inhibit 
growth of both Gram-positive and Gram-negative bacteria. 
In the study by Rivas et al., resulted that Penetratin, the 
peptide derived from the drosophila transcription factor 
antennapedia and the HIV1-Tat derived nonapeptide, be-
long to the arginine-class of peptides. These peptides ex-
hibit antimicrobial or antifungal properties 116.
CONCLUSIONS
Several variables play important role in the design, devel-
opment and delivery methods of protein and peptides. To 
make successful protein and peptide drugs, the relation-
ship between the routes of administration, pharmacoki-
netics, toxicity and clinical indication should be carefully 
balanced. Many novel systems like liposome and polymer 
offers smart alternative to solid and liquid dosage form. 
New delivery often requires invasive method but noninva-
sive delivery routes such as transdermal or pulmonary de-
livery may give up capable results for protein and peptides 
in future. The delivery of DNA and RNA in gene therapy 
and antisense therapy respectively is addressed by formu-
lations scientist. A new type of system such as biodegrad-
able nanosphere is available in near future because pres-
ently they are the focus for research by scientists. Finally 
we concluded that the protein and peptide have versatile 
applications in the field of drug delivery. 
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